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Targeted cancer therapies exploit the continued dependence of
cancer cells on oncogenic mutations. Such agents can have remark-
able activity against some cancers, although antitumor responses
are often heterogeneous, and resistance remains a clinical prob-
lem. To gain insight into factors that influence the action of a
prototypical targeted drug, we studied the action of imatinib
(STI-571, Gleevec) against murine cells and leukemias expressing
BCR-ABL, an imatinib target and the initiating oncogene for human
chronic myelogenous leukemia (CML). We show that the tumor
suppressor p53 is selectively activated by imatinib in BCR-ABL-
expressing cells as a result of BCR-ABL kinase inhibition. Inactiva-
tion of p53, which can accompany disease progression in human
CML, impedes the response to imatinib in vitro and in vivo without
preventing BCR-ABL kinase inhibition. Concordantly, p53 muta-
tions are associated with progression to imatinib resistance in
some human CMLs. Our results identify p53 as a determinant of the
response to oncogene inhibition and suggest one way in which
resistance to targeted therapy can emerge during the course of
tumor evolution.
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Most conventional cancer therapies were identified throughempirical screens for agents that preferentially kill tumor
cells compared with normal tissues. Although these agents are
effective in treating some human cancers, many tumors are
nonresponsive or evolve to a resistant state. More recently,
insights into the molecular basis of cancer have enabled the
development of more rational drugs that attack activities in-
volved in the oncogenic process (1). These ‘‘targeted’’ therapeu-
tics are often less toxic than conventional drugs and have
remarkable activity against some cancers. The effectiveness of
such agents may reflect the cancer cell’s continued dependency
on an oncogenic lesion such that it cannot tolerate the absence
of its signal, a phenomenon sometimes referred to as ‘‘oncogene
addiction’’ (2, 3). However, the molecular determinants that
contribute to the sensitivity and resistance of tumor cells to
targeted therapies are poorly understood.
Imatinib (STI-571, Gleevec) is a small-molecule inhibitor of
BCR-ABL whose effectiveness against CML makes it the par-
adigm for targeted cancer therapy. Clinical resistance to imatinib
is most often caused by point mutations in the BCR-ABL kinase
that prevent the drug–target interaction and subsequent kinase
inhibition (4), an observation that provides formal proof that the
BCR-ABL kinase is essential for imatinib sensitivity and that has
produced rational strategies to circumvent drug resistance (5, 6).
However, imatinib is generally less effective against Ph (Phil-
adelphia chromosome) acute lymphoblastic leukemia or CML
that has progressed to a more genetically complex phase known
as ‘‘blast crisis,’’ a response pattern that cannot be entirely
explained by the appearance of BCR-ABL mutants (7–9).
Presumably, other factors associated with disease progression
can impede imatinib action.
The p53 tumor suppressor provides a potent barrier to tu-
morigenesis by triggering cell-cycle checkpoints, cellular senes-
cence, or apoptosis in response to DNA damage and aberrant
proliferative signals (10, 11). Because conventional chemother-
apeutic agents can exploit the same signaling networks influ-
enced by p53 for their optimal antitumor effects, p53 mutations
acquired during tumorigenesis can promote drug resistance as a
byproduct of tumor evolution (12). However, how p53 influences
the response of tumors to targeted cancer therapy is not known.
Interestingly, p53 mutations can accompany disease progression
in human CML (13–17), and there is substantial cross-talk
between the BCR-ABL and p53 signaling networks (18–22).
Here, we examine the impact of p53 on the cellular response to
imatinib in several well characterized models of BCR-ABL-
induced malignant transformation. Our results illustrate how
factors linked to malignant progression can modulate the re-
sponse of tumor cells to targeted cancer therapy and have
implications for understanding the heterogeneous responses to
these therapies in the clinic.
Results
BCR-ABL Kinase Inhibition Induces p53. To examine the impact of
p53 on imatinib responses in vitro, we first examined BaF3 cells,
a murine Pro-B cell line that has been used extensively to study
BCR-ABL transformation and imatinib response (5). Cells were
infected with retroviruses expressing a control vector, BCR-
ABL (p210), or a BCR-ABL mutant that is insensitive to
imatinib (p210T315I), and the resulting populations were as-
sessed for p53 levels and BCR-ABL kinase activity 8 h after
imatinib addition.
As expected, p53 was expressed at low levels in the parental
cells and was not induced after imatinib treatment. In contrast,
upon imatinib treatment, p53 was induced in BCR-ABL (p210)-
expressing cells but not those expressing the BCR-ABL mutant
(T315I). Phosphorylation of p56DOK-2, which is a downstream
target of BCR-ABL signaling, was high in both BCR-ABL-
expressing populations and was repressed in treated cells ex-
pressing p210 but not the p210T315I mutant (Fig. 1a). Similar
results were observed in 32D cells and after treatment with
PD166326, a dual BCR-ABLSRC kinase inhibitor with a
distinct chemical structure (6) (Fig. 5, which is published as
supporting information on the PNAS web site, and data not
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shown). However, in a T cell leukemia line expressing BCR-ABL
(BV173), significantly higher concentrations of kinase inhibitor
were needed to induce p53 levels (e.g., 500 nM PD166326, data
not shown), suggesting that cell-line-specific differences can
exist (22).
BCR-ABL promotes oncogenesis through several down-
stream effectors, including the AktPKB kinase (23). Akt also
phosphorylates Mdm2 on Ser-166, which acts to prevent Mdm2
from efficiently targeting p53 for degradation (24). Interestingly,
phosphorylation of AktPKB was reduced in response to ima-
tinib in p210-expressing BaF3 cells, coinciding with a parallel
decrease in Ser-166-phosphorylated Mdm2 (Fig. 1b). Together,
these data imply that imatinib activates p53, at least in part,
through inhibition of BCR-ABL signaling.
p53 Contributes to Imatinib Action in Vitro. To evaluate the impact
of p53 on imatinib action, we used RNA interference (RNAi) to
suppress p53 and determined how this RNAi impacted cellular
responses to the drug. We introduced a retroviral vector coex-
pressing one of two different p53 short hairpin (sh)RNAs [p53C
(25) and p53D (26)] with GFP into BaF3 cells expressing p210
or p210T315I, and the percentage of GFP positive cells was
assessed by flow cytometry. FACS-purified GFP-positive cells
expressing the p53 shRNA showed substantial p53 knockdown
and prevented p53 induction after imatinib treatment, although
BCR-ABL kinase activity was inhibited as indicated by the
reduction in phosphorylated p56Dok-2 protein, a BCR-ABL
target (Fig. 1c). Treatment of the mixed populations with 1 M
imatinib revealed that p53 knockdown with either shRNA
conferred a selective advantage to BaF3 cells expressing p210,
because the fraction of RNAiGFP-expressing cells increased
substantially (Fig. 1d Upper; and see Fig. 6, which is published as
supporting information on the PNAS web site). By contrast, the
RNAi vector targeting p53 conferred no advantage to BaF3
cells expressing the imatinib-resistant p210T315I mutant and
neither did a control vector (Figs. 1d Lower and 6). Similar
results were observed in BCR-ABL-expressing derivatives of the
32Dmyeloid cell line (see Fig. 7, which is published as supporting
information on the PNAS web site). Thus, p53 can contribute to
the antileukemic effects of imatinib in vitro.
We next examined the relationship between p53 and imatinib
action in primary cultures enriched for hematopoietic stem cells
(HSCs). To this end, we isolated and expanded fetal liver
cells derived from crosses of p53/ mice. We transduced these
cells with a retroviral vector encoding BCR-ABL and measured
p53 expression after imatinib treatment. Similar to our findings
in the established BaF3 cell line, we found that in vitro
treatment of p53/-enriched HSCs caused decreased activation
of Akt andMdm2 and induction of p53 across a range of imatinib
concentrations (Fig. 2a).
Fig. 1. p53modulates sensitivity to imatinib in vitro. (a) Immunoblot analysis of lysates prepared from BaF3 cells stably transduced with empty vector, BCR-ABL
(p210), or mutant BCR-ABL (p210T315I) treated with imatinib for 8 h as indicated were probed for p53, phosphorylated; and total levels of p56Dok-2 protein (P-p56
and p56, respectively), and tubulin (tub) as loading control. (b) Lysates of imatinib-treated BaF3p210 cells were probed with antibodies against p53, total and
phosphorylated (Ser-473) Akt (Akt and P-Akt), and total and phosphorylated (Ser-166) Mdm2 (Mdm2 and P-Mdm2), with tub as loading control. (c) Immunoblot
of BaF3p210 cells lysates expressing either an RNAi vector targeting p53 (p53D) or control vector (Vector) treated as indicated and probed for p53,
phosphorylated (P-p56) and total (p56) p56 protein, and tub. (d) In vitro competition assay. Populations of BaF3 cells stably expressing either BCR-ABL (p210;
Upper) or the T315I mutant (p210T315I; Lower) were partially transduced with an RNAi vector against p53 (p53D) and propagated in the presence or absence
of 1 M imatinib for 1 week and then subjected to flow cytometry to determine the fraction of cells containing the RNAi vector (high GFP expression).
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To test the impact of imatinib and p53 on the proliferative
capacity of these BCR-ABL-expressing hematopoietic progen-
itors, we performed colony assays in methylcellulose. Here, cells
derived from p53/ and p53/ fetal livers were transduced with
a BCR-ABL retrovirus that coexpresses GFP such that 15–30%
of the population was infected and, thus, expressed both BCR-
ABL and GFP. Non-GFP-expressing cells served as an internal
control to assess the contribution of BCR-ABL to drug action.
Cells were plated in methylcellulose in the presence of various
concentrations of imatinib, and colonies were quantified and
inspected for GFP fluorescence 10 days later. Consistent with a
role for p53 in suppressing BCR-ABL transformation (18),
p53/ cells produced 10-fold more BCR-ABL-expressing
colonies than the p53/ controls (data not shown). As expected,
imatinib potently suppressed colony formation by p53/ HSCs
expressing BCR-ABL with an IC50 of 0.05 M. By contrast,
p53/ HSC-expressing BCR-ABL were less sensitive to BCR-
ABL inhibition, displaying an increase in IC50 (IC50  2.1 M)
(Fig. 2 b and c). Interestingly, colony formation by non-BCR-
ABL-expressing cells was not substantially influenced by p53
status (IC50 (p53/)  3.2 M, IC50 (p53/)  3.8 M) (Fig.
2d). Therefore, p53 can modulate the cellular effects of onco-
gene inhibition and contribute to the therapeutic index of
imatinib therapy.
p53 Loss Reduces Leukemic Cell Clearance and Survival in Mice
Harboring BCR-ABL Leukemias. We generated mice bearing leuke-
mias of defined p53 status by infecting HSCs derived from
p53/, p53/, and p53/ fetal livers with a BCR-ABLGFP
retrovirus transferred into lethally irradiated recipients (Fig. 3a).
Consistent with previous reports (27), these animals developed
a CML-like myeloproliferative disease and, occasionally, an
acute leukemia. Although p53 loss did not impact the range of
pathologies we observed, the onset of leukemias in mice recon-
stituted with p53/ cells was more rapid than controls, and
leukemias arising from p53/ cells invariably lost the wild-type
p53 allele (Fig. 3 b, c, and Inset). Still, BCR-ABL-expressing
leukemias arising in p53/ cells retained an intact p53 pathway,
because p53 levels and activity (as measured by expression of its
transcriptional target p21) were increased after treatment of
leukemia-bearing mice with doxorubicin, a conventional chemo-
therapeutic agent known to activate p53 (see Fig. 8, which is
Fig. 2. BCR-ABL sensitization of primary HSCs to imatinib depends on p53.
(a) Immunoblot analysis of p53/ HSCs expressing BCR-ABL before therapy
(Untr) or 8 h after treatment with different doses of imatinib, as indicated.
Lysates were immunoblotted for p53, total and phosphorylated (Ser-473) Akt
(Akt and P-Akt), phosphorylated (Ser-166) Mdm2 (P-Mdm2), and tubulin (tub).
(b) Representative microphotographs of colonies formed by p53/ or p53/
HSCs in methylcellulose untreated or treated with 1 M imatinib (Lower)
fluorescence detection of GFP expression in BCR-ABL-transformed colonies. (c
and d) Results of methylcellulose colony-formation assays, p53/ (circles) and
p53/ (squares) HSC expressing BCR-ABL (c) or control (d) were incubated
with imatinib at the indicated concentrations and colony-forming units
counted after 10 days (mean SD, n 7; P 0.016 and P 0.4 for IC50 (p53/
vs. p53/) in c and d, respectively).
Fig. 3. BCR-ABL induced leukemia in vivo. (a) Schematic of the generation
of mice harboring leukemias of defined p53 status; MIG-p210: MSCV-p210-
IRES-GFP. (b) Representative microphotographs of blood smears illustrating
the resulting pathologies. Most animals develop a CML-like myeloprolifera-
tive disease (Left), whereas some have acute leukemias (Right). (c) Latency to
leukemia onset after transplantation (day 0) of BCR-ABL-transduced HSCs of
these genotypes:p53/ (black,n 28),p53/ (blue,n 57), andp53/ (red,
n 30); P 0.0008 (p53/ vs. p53/); P 0.0005 (p53/ vs. p53/); P 0.18
(p53/ vs.p53/). (Inset) PCR to detect loss of heterozygosity in thep53 locus.
N, the knockout allele; W, the wild-type allele. Lane 1, p53/ control; lane 2,
p53/ control; lane 3–6, CML samples derived from p53/ HSCs.
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published as supporting information on the PNAS web site).
Thus, as occurs in other mouse models of BCR-ABL-induced
leukemia (28) and in human CML, p53 loss conferred an
advantage to BCR-ABL-expressing cells during leukemogenesis.
To test the impact of p53 on imatinib responses in vivo, animals
were treated upon leukemia manifestation with a 2-week twice-
daily schedule of 100 mgkg of body weight imatinib (29). One
cohort of mice was killed at various times after treatment to
assess p53 induction and BCR-ABL kinase inhibition, whereas
others were monitored for treatment responses by fluorescence
imaging or peripheral blood analysis. Consistent with in vitro
results, we found an induction of p53 in spleens of leukemic
animals but not in normal, nonleukemic mice (Fig. 4a; Fig. 9a,
which is published as supporting information on the PNAS web
site; and data not shown). Furthermore, whereas p53/ leuke-
mias showed substantial apoptosis in the peripheral blood and
were completely cleared, p53 mutant leukemias underwent less
apoptosis and only partial responses to imatinib therapy, as
determined by blood counts and fluorescence imaging (Figs. 4b
and 9b).
A cumulative analysis of the treatment data for survival (Fig.
4c) and time to relapse (see Fig. 10, which is published as
supporting information on the PNAS web site) confirmed a
modifying effect of p53 on imatinib response. Although all
animals bearing p53-deficient leukemias, generated from either
p53/ or p53/ HSCs, succumbed to their disease by day 25
after the start of imatinib therapy; nearly 40% of animals with
p53/ leukemias lived beyond this point (Fig. 4c). Although
imatinib clearly has p53-independent activities, these results
demonstrate that p53 loss can impede the response to imatinib
therapy in vivo.
Imatinib Efficiently Inhibits BCR-ABL Kinase Activity in p53-Deficient
Cells. p53 mutations produce drastic changes in cell physiology
and can promote genomic instability (30, 31). Although it is
possible that such secondary changes contribute to the decreased
imatinib sensitivity we observe in p53-deficient leukemias, our in
vitro data imply that p53 can directly influence cellular responses
to imatinib (see Figs. 1 and 2). To determine whether p53 loss
impairs imatinib action by preventing effective BCR-ABL kinase
inhibition (as occurs in cells harboring p210T315I) or through
a downstream mechanism, we monitored BCR-ABL kinase
activity in leukemic bone marrow isolates from imatinib-treated
mice. Here, phosphorylation of p56Dok-2 (a surrogate marker for
kinase activity) was repressed within 6 h after a single dose of
imatinib, and this repression was sustained for up to 24 h. More
Fig. 4. p53 and targeted therapy in murine CML. (a) Representative immunohistochemical stains to assess p53 expression in the spleens of healthy vs. leukemic
mice treated as indicated. (b) Fluorescence imaging of a cohort of p53/ and p53/ leukemia-bearing mice killed at various times after imatinib treatment.
Representative examples are shown. (c) Kaplan–Meier plot detailing survival times of leukemic mice grouped by genotype upon imatinib treatment; imatinib
was started at the onset of leukemia (day 0), and a green bar indicates the treatment interval. Leukemias are derived from BCR-ABL-transduced p53/ HSCs
(black, n  15), p53/ HSCs (blue, n  24), or p53/ (red, n  10); P 0.0002 (p53/ vs. p53/); P  0.0001 (p53/ vs. p53/); P  0.08 (p53/ vs. p53/).
(d) Bone marrow lysates of p53/ () or p53/ () leukemias were prepared from untreated animals (Untr) or at various times after a single treatment with
imatinib and subjected to immunoblotting with antibodies against phosphorylated and total p56 (P-p56, p56) and tubulin (tub).
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importantly, p53-expressing and -deficient leukemias showed
similar reductions in p56Dok-2 phosphorylation after imatinib
treatment (Fig. 4D). Therefore, p53 loss does not interfere with
the ability of imatinib to inhibit BCR-ABL kinase activity but,
instead, attenuates the cellular response to BCR-ABL inhibition.
p53 Mutations Can Accompany Progression to Imatinib Resistance in
Some CML Patients. Our studies use several well characterized
models of BCR-ABL transformation to establish that parallel
pathways independent from those emanating from the primary
oncogenic signal can influence the response to targeted cancer
therapy. Although our focus on BCR-ABL and imatinib re-
f lected our desire to study a well characterized model of targeted
therapy, our results raise the possibility that these observations
may be relevant to human CML. We therefore surveyed a
heterogeneous set of 50 specimens from CML patients, most of
whom started imatinib in late disease stages and developed
hematologic resistance to the drug (8). Ten resistant samples
(20%) had evidence of cytogenetic alterations on chromosome
17, where p53 resides, and 29 (58%) had point mutations in the
BCR-ABL kinase domain. Only two resistant specimens showed
both BCR-ABL mutations and chromosome 17 abnormalities.
However, of the resistant cases that displayed chromosome 17
alterations without BCR-ABL mutations, three of five cases
examined by DNA sequence analysis showed p53mutations that
were not present in the preimatinib samples (Table 1, which is
published as supporting information on the PNAS web site).
Thus, p53 mutations can accompany progression to imatinib
resistance in human CML.
Discussion
We show that disruption of p53 in BCR-ABL-transformed cells
can impede sensitivity to imatinib. In contrast to the complete
resistance conferred by mutations in the BCR-ABL kinase, p53
loss does not prevent BCR-ABL kinase inhibition but attenuates
its antiproliferative effects and modifies imatinib responses in
vivo. As a consequence, p53 loss impedes the clearance of
leukemic cells, which may increase the population of surviving
cells prone to additional progression- and resistance-promoting
mutations. In this manner, p53 mutations, or other mutations
affecting the p53 network, may contribute to the increase in
refractory cases in blast crisis CML or in Ph (Philadelphia
chromosome) acute lymphoblastic leukemia. Such a possibility is
consistent with our limited analysis of matched patient samples
and clinical data linking p53 mutations to blast crisis and poor
outcome and linking an apoptosis-defective p53 variant (Pro-72)
to imatinib failure in patients (15, 32).
Studies in cultured cell lines have noted variable effects of
BCR-ABL inhibition on p53 levels and activity (19–22). Using
BCR-ABL-transformed BaF3 cells, primary fetal liver HSCs,
and a murine model of CML, we see that, in all cases, p53 is
induced in response to imatinib treatment, and, at least in vitro,
this finding correlates with a decreased phosphorylation of Akt
and Mdm2. Other mechanisms may also contribute to p53
activation after imatinib treatment, including effects of BCR-
ABL on Mdm2 translation and checkpoint pathways involved in
DNA damage responses (19, 33). Paradoxically, whereas BCR-
ABL kinase inhibition can induce p53 in transformed cells, v-Abl
or BCR-ABL expression can induce p53 via the ARF pathway
to restrain transformation (ref. 18; data not shown). Presumably,
BCR-ABL simultaneously induces both pro- and antisurvival
signals that impact p53 regulation such that acute ablation of
BCR-ABL kinase activity has a greater impact on those signals
that restrain p53 action, revealing their antiproliferative poten-
tial. Other parallel signaling networks may also impact how a cell
responds to BCR-ABL inhibition, thus producing heterogeneity
in treatment responses.
The treatment of BCR-ABL-transformed cells with imatinib
represents the paradigm of targeted cancer therapy. Irrespective
of the overall impact of p53 mutations on response to imatinib
therapy in CML patients, our results have implications for the
use of targeted therapies in the clinic. For example, we demon-
strate that p53 contributes to the dependence of cancer cells on
the continued activity of an initiating oncogene, sometimes
called oncogene addiction (2), such that p53 loss attenuates the
cellular response to oncogene inactivation. These findings sug-
gest that p53 might contribute to the antitumor activity of other
targeted therapeutics, and it is noteworthy that p53 loss facili-
tates oncogene-independence and the eventual outgrowth of
tumors in conditional transgenic mice upon inactivation of the
wnt (34) oncogene. Our results also illustrate howmutations that
accompany disease progression can reduce the efficacy of tar-
geted therapy, presumably because drug action relies, in part, on
genes and processes that normally limit disease progression (e.g.,
p53). In this view, the response of tumor cells to targeted therapy
displays some parallels to conventional therapy, which can also
depend on p53 or other stress-response networks for best
efficacy. Together, these results may help explain the heteroge-
neous response of tumors to targeted therapeutics and provide
clues for their optimal use.
Materials and Methods
Cell Lines and Gene Transfer. BaF3 cells, 32D cells, and primary
HSCs were stably transduced with MSCV-IRES-GFP vectors
expressing BCR-ABL or an imatinib-resistant and kinase-active
T315I mutant (a generous gift from C. L. Sawyers, University of
California, Los Angeles). BaF3p210, BaF3T315I, or 32D
cells expressing BCR-ABL were also transduced with two RNAi
vectors against p53 [shp53C (25) shp53D1224 (26)] or an
MSCV control vector. Retroviral gene transfer was performed
as described in ref. 35.
Western Blot Analysis. Immunoblots were performed from whole-
cell lysates (36). Antibodies against -tubulin (1:5,000, B-5–1-2;
Sigma), p56 and phosphorylated p56 (1:1,000, Cat#s 3914 and
3911; Cell Signaling Technology, Beverly, MA), p53 (1:500,
p53–505; NovoCastra, Newcastle upon Tyne, U.K.), p21 (C19,
SC-397; Santa Cruz Biotechnology), phosphorylated (Ser-473)
Akt (1:1,000, Cat# 4051; Cell Signaling Technology), total Akt
(1:1000, Cat# 2966; Cell Signaling Technology), total Mdm2
(clones 2A10 and 4B11 each at 1:50, a gift from A. Levine,
Institute for Advanced Study, Princeton) (37), and phosphory-
lated (ser166) Mdm2 (1:1,000, Cat# 3521; Cell Signaling Tech-
nology) were used as probes and detected by using enhanced
chemiluminescence.
In Vitro Drug-Response Assays. For ‘‘competition’’ assays, BaF3
p210 or BaF3T315I cells were partially transduced with an
RNAi vector (p53C or p53D) or a control vector and propagated
for 1 week in the presence of absence of 1 M imatinib in
standard media. The percentage of GFP-expressing cells was
determined by flow cytometry. For methylcellulose assays, fetal
liver p53/ and p53/ HSCs (embryonic day 13–15) were
derived and retrovirally transduced as described in ref. 35.
Viability was determined by Trypan blue exclusion, and 1  103
viable cells per well were plated in Methocult GF media (Cat#
3534; StemCell Technologies, Vancouver) in the presence or
absence of imatininb. The total number and the number of
BCR-ABLGFP-expressing colony-forming units were deter-
mined 10 days after plating.
Generation of Mice. The murine model of a retrovirally induced
CML-like disease has been described in ref. 27. We modified the
model using fetal liver HSCs (embryonic day 13–15) from a cross
of p53/ C57BL6 mice. Determination of p53 status was by
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allele-specific PCR (12). After reconstitution, the mice were
monitored by blood counts. Leukemic mice (counts50,000 per
l) were treated or bone marrow and spleen were harvested for
pathology or in vitro studies. Preparation and staining of tissue
samples and cytospin preparations were according to published
recommendations (38). Mice of both p53/ and p53/ geno-
types were later diagnosed with a CML-like myeloproliferative
disease in two of three cases and an acute (mostly lymphocytic)
leukemia in one of three cases.
Treatment Studies. Leukemic mice were treated with 100 mgkg
of body weight imatinib twice daily i.p. over 2 weeks. Mice were
monitored for response by blood counts. A complete remission
was defined as absence of leukemia, and leukemia-free survival
was defined as the duration of a complete remission between
treatment and relapse. Whole-body fluorescence imaging was
performed as described in ref. 12. Disease onset and treatment
data were analyzed in Kaplan–Meier format and logrank
(Mantel–Cox) for statistical significance. IC50 data from sepa-
rate and duplicate experiments (n  7) were compared by using
a t test and are shown as mean  SD.
p53 Sequencing. Patient selection, response criteria, cytogenetics,
and analysis of BCR-ABL were as described in ref. 8. Generation
of cDNAs and sequencing of the p53 sequences corresponding
to p53 exons 2–11 were performed by using published primers
and an established protocol (39).
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